Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has completed enrollment of patients in the first of four double-blind multi-center Phase III trials for the investigational anticancer drug vandetanib for non-small cell lung cancer. Data from the study is expected in 2008.
Subscribe to our email newsletter
This Phase III trial known as ZEST is designed to assess the efficacy of vandetanib versus erlotinib in overall survival and progression-free survival in over 1,150 patients with locally advanced or metastatic non-small cell lung cancer after failure of first-line anticancer therapy. ZEST is part of a Phase III clinical trial program to gain a broad understanding of how vandetanib may benefit people with lung cancer.
Peter Langmuir, medical science director at AstraZeneca, said: “Non-small cell lung cancer is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option for people with lung cancer.”